Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

Matthias Pfisterer, Juan Carlos Prieto, Witold Ruzyllo, Peter R. Sinnaeve, Robert F. Storey, Marco Valgimigli, David J. Whellan, Petr Widimsky, John Strony, Robert A. Harrington, Kenneth W. Mahaffey, Pierluigi Tricoci, Zhen Huang, Claes Held, David J. Moliterno, Paul W. Armstrong, Frans Van de Werf, Harvey D. White, Philip E. Aylward, Lars Wallentin, Edmond Chen, Yuliya Lokhnygina, Jinglan Pei, Sergio Leonardi, Tyrus L. Rorick, Ann M. Kilian, Lisa H.K. Jennings, Giuseppe Ambrosio, Christoph Bode, Angel Cequier, Jan H. Cornel, Rafael Diaz, Aycan Erkan, Kurt Huber, Michael P. Hudson, Lixin Jiang, J. Wouter Jukema, Basil S. Lewis, A. Michael Lincoff, Gilles Montalescot, José Carlos Nicolau, Hisao Ogawa
  • New England Journal of Medicine, January 2012, New England Journal of Medicine (NEJM/MMS)
  • DOI: 10.1056/nejmoa1109719
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Professor Marco Valgimigli and Professor Giuseppe Ambrosio